Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.
Related news for (ELYM)
- eliem therapeutics announces rebranding and corporate name change to climb bio, inc.
- eliem therapeutics announces additions to its leadership team
- Eliem Therapeutics Enters $120 Million Private Placement to Acquire Tenet Medicines
- Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
- Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference